ARCHIVES

Cancel Panel Activity Ceases Due To Hammer’s Death; Oxy Chairman Promoted Funding Of Research

This article is from The Cancer Letter archive.

Vol. 17 No. 01 | January 4, 1991

Download PDF Visit The Full Archive

Related Articles

Regions Outlined In CIS Proposal

May 31, 1991

FDA Approves Lapatinib For Advanced Breast Cancer

March 30, 2007

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

October 15, 2004

FDA Approves BMS’s Yervoy For Metastatic Melanoma

March 25, 2011

Clinton to Propose Increase for NIH & NCI Significantly Higher Than In Previous Years

January 9, 1998

New Firm Steps Onto Texas Battleground for Control Over Office-Based Oncology

November 22, 1996